By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) ...
Jeito Capital said it invested in Callio Therapeutics’ $187M Series A round to support its next-generation multi-payload antibody-drug conjugates (ADCs) for cancer treatment. Callio Therapeutics ...
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...
Hosted on MSN27d
Callio raises $187m for proof-of-concept for dual-payload ADCFrazier Life Sciences led the financing round with substantial contributions from Jeito Capital and other investors including Omega Funds, Novo Holdings, ClavystBio and Pureos Bioventures.
Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases Proceeds ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results